18 December 2025 : Clinical Research
Optimizing Nivolumab Efficacy: The Role of Dosing Time in Advanced Non-Small Cell Lung Cancer
Mustafa Ersoy
ABEF 1*
DOI: 10.12659/MSM.950963
Med Sci Monit 2025; 31:e950963
Table 2 Comparison of treatment response by nivolumab administration time.
| Time of administration | Progressive disease | Stable disease | Partial response | Complete response | Total (n) | P value |
|---|---|---|---|---|---|---|
| Before 1 PM | 12 | 5 | 7 | 6 | 30 | |
| After 1 PM | 17 | 2 | 4 | 1 | 24 | |
| – number of patients. The value was calculated using the linear-by-linear association chi-square test. Statistical significance was set at | ||||||